Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Biomarker discovery for heterogeneous diseases.

Wallstrom G, Anderson KS, LaBaer J.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):747-55. doi: 10.1158/1055-9965.EPI-12-1236. Epub 2013 Mar 5.

2.

Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer.

Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, Akin D, Yan X, Chia D, Karlan B, Wong DT.

PLoS One. 2010 Dec 31;5(12):e15573. doi: 10.1371/journal.pone.0015573.

4.

Biomarker discovery using a comparative omics approach in a mouse model developing heterogeneous mammary cancer subtypes.

Pennings JL, Van Dycke KC, van Oostrom CT, Kuiper RV, Rodenburg W, de Vries A.

Proteomics. 2012 Jul;12(13):2149-57. doi: 10.1002/pmic.201100497.

PMID:
22807454
5.

Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival.

Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V, Guidos CJ, Vallis KA, Evans KR, McCready D, Leong WL, Done SJ.

PLoS One. 2012;7(2):e30992. doi: 10.1371/journal.pone.0030992. Epub 2012 Feb 20.

6.

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES.

J Proteome Res. 2013 Dec 6;12(12):5383-94. doi: 10.1021/pr400132j. Epub 2013 Oct 28.

7.
8.

Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.

Phan JH, Quo CF, Wang MD.

Prog Brain Res. 2006;158:83-108. Review.

PMID:
17027692
9.

Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome.

Mannello F, Ligi D.

BMC Cancer. 2013 Jul 12;13:344. doi: 10.1186/1471-2407-13-344. Review.

10.

Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Colburn WA, Lee JW.

Clin Pharmacokinet. 2003;42(12):997-1022. Review.

PMID:
12959633
11.

Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).

Hernández B, Parnell A, Pennington SR.

Proteomics. 2014 Jul;14(13-14):1587-92. doi: 10.1002/pmic.201300377. Epub 2014 May 16.

PMID:
24737731
12.
13.

Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.

Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS.

PLoS Med. 2008 Aug 19;5(8):e170. doi: 10.1371/journal.pmed.0050170.

14.

Proteomic approaches in lung cancer biomarker development.

Cho JY, Sung HJ.

Expert Rev Proteomics. 2009 Feb;6(1):27-42. doi: 10.1586/14789450.6.1.27. Review.

PMID:
19210125
16.

Discovery of pathway biomarkers from coupled proteomics and systems biology methods.

Zhang F, Chen JY.

BMC Genomics. 2010 Nov 2;11 Suppl 2:S12. doi: 10.1186/1471-2164-11-S2-S12.

17.

Cross-platform method for identifying candidate network biomarkers for prostate cancer.

Jin G, Zhou X, Cui K, Zhang XS, Chen L, Wong ST.

IET Syst Biol. 2009 Nov;3(6):505-12. doi: 10.1049/iet-syb.2008.0168.

PMID:
19947776
18.

Identification of breast cancer prognosis markers using integrative sparse boosting.

Ma S, Huang J, Xie Y, Yi N.

Methods Inf Med. 2012;51(2):152-61. doi: 10.3414/ME11-02-0019. Epub 2012 Feb 20.

19.
20.

Biomarker research with prospective study designs for the early detection of cancer.

Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T.

Biochim Biophys Acta. 2014 May;1844(5):874-83. doi: 10.1016/j.bbapap.2013.12.007. Epub 2013 Dec 17. Review.

PMID:
24361552
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk